α1-抗胰蛋白酶的功能及其与肺部疾病关系的研究进展

doi:10.3969/j.issn.1004-616x.2024.06.013

摘要/Abstract

摘要： α1-抗胰蛋白酶是一种丝氨酸蛋白酶抑制剂，主要由肝细胞分泌，具有抑制弹性蛋白酶、抗炎、抗凋亡和抗氧化应激等功能。肺损伤的常见原因，可由严重感染、休克、创伤及烧伤等非心源性因素诱发，病理机制为氧化应激和炎症引起的肺泡通透性升高，主要表现为肺水肿所致的肺换气功能障碍。最新研究发现α1-抗胰蛋白酶在肺损伤的发生和发展中具有重要调控作用。本文将从α1-抗胰蛋白酶的分子结构、生物学功能及其在肺部疾病中的作用等方面进行综述。

关键词: α1-抗胰蛋白酶, 肺损伤, 炎症, 细胞凋亡

中图分类号:

R114

何改花, 范珊红, 李文丽. α1-抗胰蛋白酶的功能及其与肺部疾病关系的研究进展[J]. 癌变·畸变·突变, 2024, 36(6): 502-505.

参考文献

[1] TORRES-DURÁN M, LOPEZ-CAMPOS J L, BARRECHEGUREN M, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions[J]. Orphanet J Rare Dis, 2018, 13(1): 114.
[2] LECHOWICZ U, RUDZINSKI S, JEZELA-STANEK A, et al. Post-translational modifications of circulating alpha-1-antitrypsin protein[J]. Int J Mol Sci, 2020, 21(23): 9187.
[3] STOCKLEY R A. α1-antitrypsin: a polyfunctional protein?[J]. Lancet Respir Med, 2015, 3(5): 341-343.
[4] LOPES A P, MINEIRO M A, COSTA F, et al. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency[J]. Pulmonology, 2018, 24(Suppl 1): 1-21.
[5] BAZZAN E, TINè M, BIONDINI D, et al. α1-antitrypsin polymerizes in alveolar macrophages of smokers with and without α1-antitrypsin deficiency[J]. Chest, 2018, 154(3): 607-616.
[6] STRNAD P, MCELVANEY N G, LOMAS D A. Alpha1-antitrypsin deficiency[J]. N Engl J Med, 2020, 382(15): 1443-1455.
[7] GUTTMAN O, BARANOVSKI B M, SCHUSTER R, et al. Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats[J]. Clin Exp Immunol, 2015, 179(2): 161-172.
[8] JANCIAUSKIENE S, WRENGER S, IMMENSCHUH S, et al. The multifaceted effects of Alpha1-antitrypsin on neutrophil functions[J]. Front Pharmacol, 2018, 9: 341.
[9] 张海燕, 谢世平, 吕顺武, 等. α1-抗胰蛋白酶在艾滋病湿热内蕴证病人血清中的表达及意义[J]. 时珍国医国药, 2019, 30(10): 2532-2533.
[10] GERAGHTY P, EDEN E, PILLAI M, et al. α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses[J]. Am J Respir Crit Care Med, 2014, 190(11): 1229-1242.
[11] SAPEY E. Neutrophil modulation in alpha-1 antitrypsin deficiency[J]. Chronic Obstr Pulm Dis, 2020, 7(3): 247-259.
[12] EBERT M, JERKE U, EULENBERG-GUSTAVUS C, et al. Protective α1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation[J]. J Clin Invest, 2022, 132(23): e160089.
[13] SUN R, XU Z Q, ZHU C X, et al. Alpha-1 antitrypsin in autoimmune diseases: roles and therapeutic prospects[J]. Int Immunopharmacol, 2022, 110: 109001.
[14] GREENE C M, MARCINIAK S J, TECKMAN J, et al. α1-Antitrypsin deficiency[J]. Nat Rev Dis Primers, 2016, 2: 16051.
[15] CAGNONE M, PILONI D, FERRAROTTI I, et al. A pilot study to investigate the balance between proteases and α1-antitrypsin in bronchoalveolar lavage fluid of lung transplant recipients[J]. High Throughput, 2019, 8(1): 5.
[16] STRNAD P, MANDORFER M, CHOUDHURY G, et al. Fazirsiran for liver disease associated with Alpha1-antitrypsin deficiency[J]. N Engl J Med, 2022, 387(6): 514-524.
[17] GUYOT N, WARTELLE J, MALLERET L, et al. Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema[J]. Am J Pathol, 2014, 184(8): 2197-2210.
[18] JANCIAUSKIENE S, WELTE T. Well-known and less well-known functions of alpha-1 antitrypsin. its role in chronic obstructive pulmonary disease and other disease developments[J]. Ann Am Thorac Soc, 2016, 13(Sup 4): 280-288.
[19] AMBADE V N, AMBADE S, GUNDPATIL D B, et al. Biochemical alteration in serum alpha-1 antitrypsin levels in patients with chronic obstructive pulmonary disease[J]. Indian J Clin Biochem, 2024: 1915.
[20] HE G H, YU W H, LI H W, et al. Alpha-1 antitrypsin protects against phosgene-induced acute lung injury by activating the ID1-dependent anti-inflammatory response[J]. Eur J Pharmacol, 2023, 957: 176017.
[21] POTT G B, CHAN E D, DINARELLO C A, et al. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood[J]. J Leukoc Biol, 2009, 85(5): 886-895.
[22] PARR D G, LARA B. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature[J]. Drug Des Devel Ther, 2017, 11: 2149-2162.
[23] BELCHAMBER K B R, WALKER E M, STOCKLEY R A, et al. Monocytes and macrophages in alpha-1 antitrypsin deficiency[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 3183-3192.
[24] DE LOYOLA M B, DOS REIS T T A, DE OLIVEIRA G X L M, et al. Alpha-1-antitrypsin: a possible host protective factor against Covid-19[J]. Rev Med Virol, 2021, 31(2): e2157.
[25] SUBRAMANIYAM D, STEELE C, K-HNLEIN T, et al. Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo[J]. Inflamm Res, 2010, 59(7): 571-578.
[26] LIM J H, PARK S M, YOOK J M, et al. Alpha-1 antitrypsin inhibits formaldehyde-induced apoptosis of human peritoneal mesothelial cells[J]. Perit Dial Int, 2020, 40(2): 124-131.
[27] LOISON F, ZHU H Y, KARATEPE K, et al. Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation[J]. J Clin Invest, 2014, 124(10): 4445-4458.
[28] MCELVANEY O F, FRAUGHEN D D, MCELVANEY O J, et al. Alpha-1 antitrypsin deficiency: current therapy and emerging targets[J]. Expert Rev Respir Med, 2023, 17(3): 191-202.
[29] FENG Y L, HU L Q, XU Q, et al. Cytoprotective role of alpha-1 antitrypsin in vascular endothelial cell under hypoxia/reoxygenation condition[J]. J Cardiovasc Pharmacol, 2015, 66(1): 96-107.
[30] KAHNERT K, J-RRES R A, BEHR J, et al. The diagnosis and treatment of COPD and its comorbidities[J]. Dtsch Arztebl Int, 2023, 120(25): 434-444.
[31] LEAP J, ARSHAD O, CHEEMA T, et al. Pathophysiology of copd[J]. Crit Care Nurs Q, 2021, 44(1): 2-8.
[32] CHUANG H C, CHEN Y Y, HSIAO T C, et al. Alteration in angiotensin-converting enzyme 2 by PM1 during the development of emphysema in rats[J]. ERJ Open Res, 2020, 6(4): 00174-02020.
[33] GOOPTU B, DICKENS J A, LOMAS D A. The molecular and cellular pathology of α1-antitrypsin deficiency[J]. Trends Mol Med, 2014, 20(2): 116-127.
[34] HIRAI T. α1-Antitrypsin deficiency[J]. Nihon Rinsho, 2016, 74(5): 869-873.
[35] MCELVANEY N G. Diagnosing α1-antitrypsin deficiency: how to improve the current algorithm[J]. Eur Respir Rev, 2015, 24(135): 52-57.
[36] BIANCHERA A, ALOMARI E, MICHIELON A, et al. Recombinant alpha-1 antitrypsin as dry powder for pulmonary administration: a formulative proof of concept[J]. Pharmaceutics, 2022, 14(12): 2754.
[37] TOPIC A, MILOVANOVIC V, LAZIC Z, et al. Oxidized alpha-1-antitrypsin as a potential biomarker associated with onset and severity of chronic obstructive pulmonary disease in adult population[J]. COPD, 2018, 15(5): 472-478.
[38] D'AMATO M, CAMPAGNOLI M, IADAROLA P, et al. Could the oxidation of α1-antitrypsin prevent the binding of human neutrophil elastase in COVID-19 patients?[J]. Int J Mol Sci, 2023, 24(17): 13533.
[39] GAO W X, ZHAO J B, KIM H, et al. α1-Antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death[J]. J Heart Lung Transplant, 2014, 33(3): 309-315.
[40] LI Y, KROWKA M J, QI Y W, et al. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival[J]. J Thorac Oncol, 2011, 6(2): 291-295.
[41] SCHWARTZ A G, ROTHROCK M, YANG P, et al. Increased cancer risk among relatives of nonsmoking lung cancer cases[J]. Genet Epidemiol, 1999, 17(1): 1-15.
[42] ERCETIN E, RICHTMANN S, DELGADO B M, et al. Clinical significance of SERPINA1 gene and its encoded Alpha1-antitrypsin protein in NSCLC[J]. Cancers, 2019, 11(9): 1306.